HC Wainwright Reaffirms Buy Rating for Bellerophon Therapeutics (BLPH)

HC Wainwright reaffirmed their buy rating on shares of Bellerophon Therapeutics (NASDAQ:BLPH) in a research report released on Tuesday.

Separately, ValuEngine upgraded Bellerophon Therapeutics from a strong sell rating to a sell rating in a research report on Thursday, March 15th.

How to Become a New Pot Stock Millionaire

Bellerophon Therapeutics (NASDAQ:BLPH) opened at $2.02 on Tuesday. The company has a market capitalization of $110.72, a PE ratio of -1.46 and a beta of -0.32. Bellerophon Therapeutics has a 1 year low of $1.00 and a 1 year high of $2.74.

A number of institutional investors have recently bought and sold shares of BLPH. Virtu Financial LLC bought a new position in Bellerophon Therapeutics in the fourth quarter valued at about $146,000. Bank of New York Mellon Corp bought a new position in Bellerophon Therapeutics in the fourth quarter valued at about $458,000. EAM Investors LLC bought a new position in Bellerophon Therapeutics in the fourth quarter valued at about $614,000. Vanguard Group Inc. raised its position in Bellerophon Therapeutics by 52.6% in the second quarter. Vanguard Group Inc. now owns 612,641 shares of the biotechnology company’s stock valued at $821,000 after purchasing an additional 211,111 shares during the last quarter. Finally, Renaissance Technologies LLC raised its position in Bellerophon Therapeutics by 25.3% in the fourth quarter. Renaissance Technologies LLC now owns 927,200 shares of the biotechnology company’s stock valued at $2,392,000 after purchasing an additional 187,200 shares during the last quarter. Hedge funds and other institutional investors own 59.86% of the company’s stock.

TRADEMARK VIOLATION WARNING: “HC Wainwright Reaffirms Buy Rating for Bellerophon Therapeutics (BLPH)” was posted by Ticker Report and is the property of of Ticker Report. If you are reading this report on another website, it was copied illegally and republished in violation of U.S. & international copyright & trademark law. The original version of this report can be read at https://www.tickerreport.com/banking-finance/3294505/hc-wainwright-reaffirms-buy-rating-for-bellerophon-therapeutics-blph.html.

Bellerophon Therapeutics Company Profile

Bellerophon Therapeutics, Inc is a clinical-stage therapeutics company. The Company is focused on developing products at the intersection of drugs and devices that address medical needs in the treatment of cardiopulmonary diseases. The Company is focused on the development of its nitric oxide therapy for patients with pulmonary hypertension (PH), using its delivery system, INOpulse, with pulmonary arterial hypertension (PAH) as the lead indication.

Receive News & Ratings for Bellerophon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bellerophon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

LPL Financial LLC Buys Shares of 35,476 Goldman Sachs ActiveBeta Europe Equity ETF
LPL Financial LLC Buys Shares of 35,476 Goldman Sachs ActiveBeta Europe Equity ETF
Lourd Capital LLC Acquires 930 Shares of Amazon.com, Inc.
Lourd Capital LLC Acquires 930 Shares of Amazon.com, Inc.
Leucadia National Corp Acquires New Position in Comcast Co.
Leucadia National Corp Acquires New Position in Comcast Co.
Honeywell  Shares Sold by Lazard Asset Management LLC
Honeywell Shares Sold by Lazard Asset Management LLC
Ladenburg Thalmann Financial Services Inc. Has $330,000 Holdings in John Hancock Multifactor Large Cap ETF
Ladenburg Thalmann Financial Services Inc. Has $330,000 Holdings in John Hancock Multifactor Large Cap ETF
Vestpro Financial Partners Inc. dba CPF Texas Purchases New Position in CVS Health
Vestpro Financial Partners Inc. dba CPF Texas Purchases New Position in CVS Health


© 2006-2018 Ticker Report. Google+.